Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Correction to: Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.

Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, Centonze D, Modugno N.

Neurol Sci. 2019 Jul 1. doi: 10.1007/s10072-019-03972-7. [Epub ahead of print]

PMID:
31257551
2.

Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.

Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, Centonze D, Modugno N.

Neurol Sci. 2019 May 20. doi: 10.1007/s10072-019-03920-5. [Epub ahead of print] Erratum in: Neurol Sci. 2019 Jul 1;:.

PMID:
31111272
3.

Improvement of lateral axial dystonia following prismatic correction of oculomotor control disorders in Parkinson's disease.

Santilli M, Meglio M, Varanese S, Lena F, Iezzi E, Grillea G, Modugno N.

J Neurol. 2016 Feb;263(2):403-404. doi: 10.1007/s00415-015-8017-8. Epub 2016 Jan 11. No abstract available.

PMID:
26754006
4.

Electrophysiological indices of interference resolution covary with individual fluid intelligence: investigating reactive control processes in a 3-back working memory task.

Perfetti B, Varanese S, Mancino E, Mercuri P, Tesse M, Franciotti R, Bonanni L, Thomas A, Onofrj M.

Neuroimage. 2014 Jun;93 Pt 1:146-53. doi: 10.1016/j.neuroimage.2014.02.020. Epub 2014 Feb 25.

PMID:
24582918
5.

Responsiveness of dysphagia to acute L-Dopa challenge in progressive supranuclear palsy.

Varanese S, Di Ruscio P, Ben M' Barek L, Thomas A, Onofrj M.

J Neurol. 2014 Feb;261(2):441-2. doi: 10.1007/s00415-013-7232-4. Epub 2014 Jan 12. No abstract available.

PMID:
24413640
6.

Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence.

Varanese S, Perfetti B, Gilbert-Wolf R, Thomas A, Onofrj M, Di Rocco A.

Int J Geriatr Psychiatry. 2013 Oct;28(10):1095-7. doi: 10.1002/gps.3952. No abstract available.

PMID:
24038163
7.

Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond.

Onofrj M, Ciccocioppo F, Varanese S, di Muzio A, Calvani M, Chiechio S, Osio M, Thomas A.

Expert Rev Neurother. 2013 Aug;13(8):925-36. doi: 10.1586/14737175.2013.814930. Review.

PMID:
23965166
8.

Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies.

Onofrj M, Varanese S, Bonanni L, Taylor JP, Antonini A, Valente EM, Petrucci S, Stocchi F, Thomas A, Perfetti B.

J Neurol. 2013 Jul;260(7):1731-42. doi: 10.1007/s00415-013-6853-y. Epub 2013 Feb 12.

9.

Irrelevant features of a stimulus can either facilitate or disrupt performance in a working memory task: the role of fluid intelligence.

Perfetti B, Tesse M, Varanese S, Saggino A, Onofrj M.

PLoS One. 2011;6(10):e26249. doi: 10.1371/journal.pone.0026249. Epub 2011 Oct 14.

10.

Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson's disease.

Varanese S, Perfetti B, Ghilardi MF, Di Rocco A.

PLoS One. 2011 Mar 18;6(3):e17846. doi: 10.1371/journal.pone.0017846.

11.

Treatment of advanced Parkinson's disease.

Varanese S, Birnbaum Z, Rossi R, Di Rocco A.

Parkinsons Dis. 2011 Feb 7;2010:480260. doi: 10.4061/2010/480260.

12.

Attention modulation regulates both motor and non-motor performance: a high-density EEG study in Parkinson's disease.

Perfetti B, Moisello C, Lanzafame S, Varanese S, Landsness EC, Onofrj M, Di Rocco A, Tononi G, Ghilardi MF.

Arch Ital Biol. 2010 Sep;148(3):279-88.

13.

Protracted benefit from paradoxical kinesia in typical and atypical parkinsonisms.

Bonanni L, Thomas A, Anzellotti F, Monaco D, Ciccocioppo F, Varanese S, Bifolchetti S, D'Amico MC, Di Iorio A, Onofrj M.

Neurol Sci. 2010 Dec;31(6):751-6. doi: 10.1007/s10072-010-0403-5. Epub 2010 Sep 22.

PMID:
20859648
14.

Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease.

Varanese S, Perfetti B, Monaco D, Thomas A, Bonanni L, Tiraboschi P, Onofrj M.

J Neurol. 2010 Jun;257(6):1004-11. doi: 10.1007/s00415-010-5453-3. Epub 2010 Jan 22.

PMID:
20094726
15.

NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.

Varanese S, Howard J, Di Rocco A.

Mov Disord. 2010 Mar 15;25(4):508-10. doi: 10.1002/mds.22917. No abstract available.

PMID:
20014061
16.

Fava beans and Parkinson's disease: useful 'natural supplement' or useless risk?

Raguthu L, Varanese S, Flancbaum L, Tayler E, Di Rocco A.

Eur J Neurol. 2009 Oct;16(10):e171. doi: 10.1111/j.1468-1331.2009.02766.x. Epub 2009 Aug 12. No abstract available.

PMID:
19678834
17.

Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: a comparison with other clinical executive tasks.

Perfetti B, Varanese S, Mercuri P, Mancino E, Saggino A, Onofrj M.

Parkinsonism Relat Disord. 2010 Jan;16(1):46-50. doi: 10.1016/j.parkreldis.2009.07.011. Epub 2009 Aug 7.

PMID:
19665420
18.

Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism.

Invernizzi F, Varanese S, Thomas A, Carrara F, Onofrj M, Zeviani M.

Neuromuscul Disord. 2008 Jun;18(6):460-4. doi: 10.1016/j.nmd.2008.04.005. Epub 2008 May 27.

PMID:
18502641
19.

EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M.

Brain. 2008 Mar;131(Pt 3):690-705. doi: 10.1093/brain/awm322. Epub 2008 Jan 17.

PMID:
18202105
20.

Delayed blink reflex in dementia with Lewy bodies.

Bonanni L, Anzellotti F, Varanese S, Thomas A, Manzoli L, Onofrj M.

J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1137-9.

21.

Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.

Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M.

Mov Disord. 2007 Oct 31;22(14):2097-103.

PMID:
17685467
22.

End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D'Andreagiovanni A, Stocchi F, Onofrj M.

J Neurol. 2006 Dec;253(12):1633-9.

PMID:
17219034

Supplemental Content

Loading ...
Support Center